Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 7.04 mg - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

United States - English - NLM (National Library of Medicine)

abbvie inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 10 mg in 1 ml - nimbex is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use nimbex is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. nimbex is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to nimbex have been reported [see warnings and precautions (5.4)] . the use of 10 ml nimbex multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and precautions (5.2) and use in specific populations (8.4)] . risk summary there are no adequate

United States - English - NLM (National Library of Medicine)

abbvie inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium 10 mg in 1 ml - nimbex is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use nimbex is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. - nimbex is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to nimbex have been reported [see warnings and precautions ( 5.4 )] . - the use of 10 ml nimbex multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation contains benzyl alcohol [see warnings and precautions ( 5.2 ) and use in specific populations ( 8.4 )] . risk summary the 10 ml ni

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 14.07 mg (equivalent: cisatracurium, qty 10.5 mg) - injection, solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - cisatracurium besilate, quantity: 28.14 mg (equivalent: cisatracurium, qty 21 mg) - injection, solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium injection is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisatracurium besilate -

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) - cisatracurium besylate injection is indicated: - as an adjunct to general anesthesia to facilitate tracheal intubation in adults and in pediatric patients 1 month to 12 years of age - to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the icu - to provide skeletal muscle relaxation during surgical procedures via infusion in pediatric patients 2 years and older limitations of use cisatracurium besylate injection is not recommended for rapid sequence endotracheal intubation due to the time required for its onset of action. - cisatracurium besylate injection is contraindicated in patients with known hypersensitivity to cisatracurium. severe anaphylactic reactions to cisatracurium besylate injection have been reported [see warnings and precautions (5.4)] . - the use of 10 ml cisatracurium besylate injection multiple-dose vials is contraindicated for use in pediatric patients less than 1 month of age and low birth-weight infants because the formulation co

Canada - English - Health Canada

accord healthcare inc - cisatracurium (cisatracurium besylate) - solution - 2mg - cisatracurium (cisatracurium besylate) 2mg - neuromuscular blocking agents

United States - English - NLM (National Library of Medicine)

hikma farmaceutica - cisatracurium besylate (unii: 80ys8o1mbs) (cisatracurium - unii:qx62kli41n) -